Search hospitals > Tennessee > Germantown
Stern Cardiovascular Foundation, Inc.
Claim this profileGermantown, Tennessee 38138
Global Leader in Heart Failure
Conducts research for Cardiovascular Disease
Conducts research for Atrial Fibrillation
Conducts research for High Blood Pressure
Conducts research for Cardiomyopathy
56 reported clinical trials
3 medical researchers
Summary
Stern Cardiovascular Foundation, Inc. is a medical facility located in Germantown, Tennessee. This center is recognized for care of Heart Failure, Cardiovascular Disease, Atrial Fibrillation, High Blood Pressure, Cardiomyopathy and other specialties. Stern Cardiovascular Foundation, Inc. is involved with conducting 56 clinical trials across 58 conditions. There are 3 research doctors associated with this hospital, such as Frank McGrew, M.D., John Jeffries, MD, and John Lynn Jefferies.Top PIs
Frank McGrew, M.D.Stern Cardiovascular6 years of reported clinical research
Studies Heart Failure
Studies Cardiovascular Disease
3 reported clinical trials
4 drugs studied
John Jeffries, MDStern Cardiovascular Foundation3 years of reported clinical research
Studies Heart Failure
Studies Congestive Heart Failure
3 reported clinical trials
3 drugs studied
John Lynn JefferiesThe Stern Cardiovascular Foundation3 years of reported clinical research
Studies Heart Failure
Studies Obesity
1 reported clinical trial
2 drugs studied
Clinical Trials running at Stern Cardiovascular Foundation, Inc.
Heart Failure
Bleeding
Emergency Surgery
Invasive Procedure
Spironolactone
for Heart Failure
Heart failure with preserved ejection fraction (HFPEF) is common and deadly but without therapy. Inconclusive studies such as TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) suggest spironolactone may be effective in HFPEF, but it is generic and will not be studied by industry. SPIRRIT is a unique Registry-Randomized Clinical Trial (RRCT) that will test the hypothesis that spironolactone plus standard of care compared to standard of care alone reduces the composite of CV mortality and HF hospitalization as follows: Population: HFPEF patients in the Swedish Heart Failure Registry and HFPEF patients in US. HFPEF defined as symptoms/signs of HF, elevated NTproBNP (B-type Natriuretic Peptide; N-terminal pro b-type Natriuretic Peptide) and EF\>=40%. Intervention and control: Randomized 1:1 to intervention: spironolactone + usual care vs. control: usual care alone. Outcome: Primary outcome cardiovascular death or time to HF hospitalization. Secondary outcomes include hospitalization for various causes, adverse events and treatment adherence. In Sweden outcomes are obtained automatically by linking with the Population, Patient and Drug Dispensed Registries. In the US, outcomes will be reported by sites and supplemented by data from a call center. The trial is event-driven with enrollment 7 years and study duration 9 years. For the primary outcome (CV Death or first HF hospitalization) with an event target of 721 events the sample size requires 1985 patients conservatively rounded to approximately 2000 patients.
Recruiting3 awards Phase 37 criteria
LINQ Sensor Algorithm
for Heart Failure
This trial tests a small device that monitors heart activity in patients with moderate heart failure. The device uses special software to help doctors manage patient care more effectively.
Recruiting0 awards N/A5 criteria
CCM Therapy
for Heart Failure
This trial tests a device that helps the heart pump better in patients with moderate heart failure. It targets those whose heart's pumping ability is moderately reduced. The device works by giving the heart small electrical boosts. Several new devices for the treatment of heart failure patients have been introduced and are increasingly used in medical practice or are under evaluation.
Recruiting0 awards N/A7 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Stern Cardiovascular Foundation, Inc.?
Stern Cardiovascular Foundation, Inc. is a medical facility located in Germantown, Tennessee. This center is recognized for care of Heart Failure, Cardiovascular Disease, Atrial Fibrillation, High Blood Pressure, Cardiomyopathy and other specialties. Stern Cardiovascular Foundation, Inc. is involved with conducting 56 clinical trials across 58 conditions. There are 3 research doctors associated with this hospital, such as Frank McGrew, M.D., John Jeffries, MD, and John Lynn Jefferies.